Nebido (Testosterone Undecanoate)

Testosterone undecanoate is hydrolyzed after intramuscular injection to release testosterone. The hormone binds to intracellular androgen receptors, influencing gene expression that promotes anabolic effects, spermatogenesis, and development of secondary sexual characteristics, thereby compensating for low endogenous testosterone.

The dosing regimen for Nebido is determined by the prescribing physician based on the individual’s clinical condition, serum testosterone levels, and response to therapy. Physicians typically follow approved labeling guidelines, and patients should follow the specific instructions provided by their healthcare professional.

Nebido is contraindicated in women who are pregnant or breastfeeding. Testosterone can cause fetal harm and may affect milk production. Women of childbearing potential should use effective contraception during treatment and for a period after the last dose as advised by their clinician.

To request Nebido, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Nebido offers a long‑acting intramuscular formulation that requires dosing every 10‑12 weeks, compared with shorter‑acting testosterone esters that may need weekly or bi‑weekly injections. This extended interval can improve adherence and reduce injection‑site discomfort, while providing comparable efficacy in restoring testosterone levels.

Nebido should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and do not freeze or shake the product. Maintaining the cold chain ensures the stability and potency of the testosterone undecanoate suspension.

Nebido is given as an intramuscular injection, typically into the gluteal muscle. A healthcare professional administers the dose using a sterile technique. The injection volume and frequency are determined by the prescribing clinician, and patients should receive the injection in a clinical setting.

Serious risks include polycythemia (elevated red blood cell count), cardiovascular events such as thrombosis, liver toxicity, worsening of prostate disease, and severe allergic reactions. Regular monitoring of hematocrit, liver function, and prostate health is essential to mitigate these risks.

Nebido is contraindicated in men with known hypersensitivity to testosterone undecanoate, those with prostate or breast cancer, severe untreated sleep apnea, uncontrolled heart failure, or significant liver disease. Women who are pregnant, breastfeeding, or of childbearing potential without effective contraception should also avoid this medication.